We demonstrated that CHRM4/IFNA17-activated prostate cancer cells might interact with M2-type TAMs to promote NED and immune checkpoint pathways in prostate cancer cells, contributing to the development of an immunosuppressive TME and NEPC. Here, CHRM4 is linked to prostate cancer.